A Virginia Commonwealth University Massey Cancer Center research team has received a renewal grant totaling nearly $1.3 million from the National Cancer Institute to improve the activity of a novel class of agents, known as histone deacetylase inhibitors, in the treatment of leukemia and other blood malignancies. Read more.
« Instructional technology creates a ‘learner-centered environment’ | Main | VCU infectious diseases expert is principal investigator of grant to support women health care professionals from developing countries »